TSE:PRM
Harvest Big Pharma Split Corp. (PRM.TO)
Financials 
Technical Analysis 
Jul 24, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Harvest Big Pharma Split Corp. (PRM-T) is viewed positively by analysts, with consistent support from its performance and strong dividend yields. The company's strategy of holding a portfolio of the world's largest pharmaceutical and biotechnology firms allows it to generate enhanced distributions for investors. Recent reviews highlight the fund's ability to maintain value during market downturns, showcasing its resilience. Analysts recommend strategic stop-loss placements and project upsides in share prices, indicating confidence in future growth. Overall, PRM-T stands out due to its solid yield, effective management, and the stable pharma sector's performance.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentWe reiterate PRM, a portfolio of the 10 world's largest pharma and biotech companies, as a TOP PICK. The fund manages a balance of underlying shares with dividends and options to create an enhanced yield for investors, which presently yields over 8%. We recommend trailing up the stop (from $10) to $13, looking to achieve $18 -- upside over 18%. Yield 8.2%
(Analysts’ price target is $32.78)Premium contentPRM hold a portfolio of 10 of the world's largest pharmaceutical and biotechnology companies. The fund managers use a balance of the underlying shares with dividends and options to create an enhanced yield. We like that recent earnings show healthy and growing cash reserves. The shares held their value during the severe market downturns in 2018 and 2022 -- actually increasing 11% in each -- providing good market volatility protection. We recommend setting a stop-loss at $10.00, looking to achieve $15.00 -- upside potential of 18%. Yield 7.2%
- «
- ‹
- 1
- ›
- »
Popular Articles
Harvest Big Pharma Split Corp. (PRM.TO) Frequently Asked Questions
What is Harvest Big Pharma Split Corp. stock symbol?
Harvest Big Pharma Split Corp. is a Canadian stock, trading under the symbol PRM.TO (previously PRM-T on Stockchase) on the Toronto Stock Exchange (PRM-CT). It is usually referred to as TSX:PRM or PRM.TO
Is Harvest Big Pharma Split Corp. a buy or a sell?
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on PRM.TO (previously PRM-T on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Harvest Big Pharma Split Corp..
Is Harvest Big Pharma Split Corp. a good investment or a top pick?
Harvest Big Pharma Split Corp. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-07-07. Read the latest stock experts ratings for Harvest Big Pharma Split Corp..
Why is Harvest Big Pharma Split Corp. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Harvest Big Pharma Split Corp..
Is Harvest Big Pharma Split Corp. worth watching?
Harvest Big Pharma Split Corp. is followed by 13 investors on Stockchase and is a trending stock that is worth watching.
What is Harvest Big Pharma Split Corp. stock price?
On 2026-07-24, Harvest Big Pharma Split Corp. (PRM.TO) stock closed at a price of $14.50.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
We again reiterate PRM, holder of a basket of top pharma companies with enhanced distributions as a TOP PICK. Recently announced distributions provide a strong yield and the pharma sector as a whole is performing consistently. We continue to recommend a stop at $13, looking to achieve $17 -- upside potential of 17%. Yield 8.6%